TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release syndrome (CRS) but only 2% prevalence of grades ≥ 3 CRS. The analysis of 2192 patients revealed 38% and 26% prevalence of all-grade and grades ≥ 3 neutropenia…
Leave a Comment Leave a Comment
